Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Switzerland

Roche's Outperformance In Emerging Markets Dampened By Currency Effects

February 2011 | Industry Trend Analysis

BMI View: In the short term, BMI believes Swiss drugmaker Roche will be forced to implement cost- cutting measures in order to maintain profit growth, given the Swiss currency's negative effects on the competitiveness of the firm's exports. Nevertheless, Roche's strengths in the personalised medicines sector, coupled with its strong pipeline and large product portfolio - containing mainly hard-to-copy biological drugs - places the firm in a strong position for revenue growth in the long

To read the full article, please choose one of the following options:

Subcribers please log in

Western Europe InsightWestern Europe Channels Western Europe Countries